Dow Today: Travelers Companies (TRV) Leads The Day Higher, Pfizer (PFE) Lags
The Dow Jones Industrial Average (^DJI) is trading down 13.0 points at 13,200 as of Tuesday, May 1, 2012, 9:35 a.m. ET. During this time, 25.6 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 743.8 million. The NYSE advances/declines ratio sits at 1,468 issues advancing vs. 1,199 declining with 178 unchanged. The Dow component leading the way higher looks to be Travelers Companies (NYSE:TRV), which is sporting a 38-cent gain (+0.6%) bringing the stock to $64.70. Volume for Travelers Companies currently sits at 94,538 shares traded vs. an average daily trading volume of 3.1 million shares. Travelers Companies has a market cap of $24.9 billion and is part of the financial sector and insurance industry. Shares are up 8.7% year to date as of Monday's close. The stock's dividend yield sits at 2.9%. The Travelers Companies, Inc., through its subsidiaries, provides various commercial and personal property and casualty insurance products and services to businesses, government units, associations, and individuals primarily in the United States. The company has a P/E ratio of 18.6, below the average insurance industry P/E ratio of 18.8 and above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Travelers Companies as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.
- You can view the full Travelers Companies Ratings Report.
- See our dividend calendar or top-yielding stocks list.
- You can view the full Pfizer Ratings Report.
Latest Headlines about PFE
-
Allocate Assets to Buy-Rated Dow Stocks
08:50AM 05/22/13
-
Cramer: A Pile of Simply Horrendous Advice
11:58AM 05/20/13
-
Aveo Screwed Up but Its Kidney Cancer Drug Is Real
09:24AM 05/15/13
-
5 Huge Stocks to Trade: Must-See Charts
11:29AM 05/09/13
-
Cramer's 'Mad Money' Recap: Giving Credit Where It's Due
08:10PM 05/08/13
-
It's Pipeline That Matters Most
04:30AM 05/04/13
-
Cramer: Big Pharma Has Lost Its Way
11:49AM 05/03/13
Latest from TheStreet Wire
-
Infosys Ltd (INFY): Today's Featured Technology Laggard
05:01PM 05/24/13
-
Williams Companies Inc (WMB): Today's Featured Basic Materials Laggard
05:01PM 05/24/13
-
Trimble Navigation Limited (TRMB): Today's Featured Electronics Laggard
05:01PM 05/24/13
-
Deere & Co (DE): Today's Featured Industrial Laggard
05:01PM 05/24/13
-
Eli Lilly And Company (LLY): Today's Featured Drugs Laggard
05:01PM 05/24/13
-
Sap AG (SAP): Today's Featured Computer Software & Services Laggard
05:01PM 05/24/13
-
Duke Energy Corporation (DUK): Today's Featured Utilities Laggard
05:01PM 05/24/13
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
